Ferit Aslan, Kübra Aydın, Banu Öztürk, Umut Demirci

Vemurafenib Tedavisi Sırasında Akciğer Progresyonu Gösteren Metastatik Malign Melanom Olgusu

Yetmiş yaşında kadın sağ inguinal bölgede akıntılı şişliği olması üzerine başvurdu. Lezyon biyopsisi malign melanomla uyumluydu. Toraks ve batın görüntülemelerinde metastaz bulguları mevcuttu. Birinci basamak temozolomid sonrası lezyon bölgesinde progresyon nedeni ile palyatif radyoterapi uygulandı. BRAF-V600E mutasyonu nedeni ile vemurafenib başlandı. Tedavinin ikinci ayında çok iyi kısmi yanıt elde edildi. Tedavinin 5. ayında sol akciğerde lokal progresyon izlenirken diğer bölgelerde kısmi yanıtı devam ediyordu. Palyatif radyoterapi sonrası vemurafenib tedavisine devam edildi.

Anahtar Kelimeler:

Malignmelanom, Vemurafenib, Radyoterapi

A Case of Metastatic Malignant Melanoma who Lung Progressed During Vemurafenib Treatment

A 70 year-old women admitted to our hospital with a swelling and discharge of the right inguinal site. Biopsy results was consisted with malignant melanoma. Imaging of thorax and abdomen showed metastatic disease. After first-line temozolamide treatment, palliative radiotherapy was applied to primary site because of progression. After detection of BRAF-V600E mutation, vemurafenib treatment was initiated. Treatment response to vemurafenib was very good partial response after second months of the treatment. Although locally progression of the left lung was seen after fifth months of therapy, partial response remained on the other sites, she was still on the treatment with vemurafenib.

Keywords:

Malignant Melanoma, Vemurafenib, Radiotherapy,

PDF

___

Kaufman HL, Kirkwood JM, Hodi FS, et al. The Society for Immunotherapy of Cancer consensus statement on tumour immunotherapy for the treatment of cutaneous melanoma. Nat Rev Clin Oncol 2013;10:588-98
Holderfield M, Deuker MM, McCormick F, McMahon M. Targeting RAF kinases for cancer therapy: BRAF-mutated melanoma and beyond. Nat Rev Cancer 2014;14:455-67
Curtin JA, Fridlyand J, Kageshita T, et al. Distinctsets of genetic alterations in melanoma. N Engl J Med 2005;353:2135-47
Bollag G, Hirth P, Tsai J, et al. Clinicalefficacy of a RAF inhibitör needs broad target blockade in BRAF- mutant melanoma. Nature 2010;467:596-9
McArthur GA, Chapman PB, Robert C,et. al. Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM- 3): extended follow-up of a phase 3, randomised, open-label study. Lancet Oncol 2014;15:323-32
Chapman PB, Hauschild A, Robert C, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011;364:2507-16
Camidge DR, Pao W, Sequist LV. Acquired resistance to TKIs in solid tumours: learning from lung cancer. Nat Rev Clin Oncol 2014;11:473-81
Chan MM, Haydu LE, Menzies AM, et. al. The nature and management of metastatic melanoma after progression on BRAF inhibitors: Effects of extended BRAF 10.1002/cncr.28851 2014;Jul 1. doi:
Yang JJ, Chen HJ, Yan HH, et al. Clinical modes of EGFR subsequent management in advanced non-small cell lung cancer. Lung Cancer 2013;79:33-9 failure and
Baroudjian B, Boussemart L, Routier E. et al. Dramatic response to radiotherapy combined with vemurafenib. Is vemurafenib a radiosensitizer? Eur J Dermatol 2014;24:265-7